Bionano Genomics, Inc.
Index- P/E- EPS (ttm)-0.33 Insider Own2.00% Shs Outstand284.61M Perf Week-17.28%
Market Cap371.39M Forward P/E- EPS next Y-0.37 Insider Trans0.18% Shs Float284.15M Perf Month-14.65%
Income-92.40M PEG- EPS next Q-0.09 Inst Own25.80% Short Float13.62% Perf Quarter-48.06%
Sales20.50M P/S18.12 EPS this Y33.60% Inst Trans-4.39% Short Ratio6.00 Perf Half Y-57.05%
Book/sh1.09 P/B1.23 EPS next Y5.10% ROA-25.60% Target Price8.67 Perf Year-80.35%
Cash/sh0.78 P/C1.72 EPS next 5Y- ROE-27.70% 52W Range1.16 - 7.31 Perf YTD-55.18%
Dividend- P/FCF- EPS past 5Y33.30% ROI-21.00% 52W High-81.67% Beta2.18
Dividend %- Quick Ratio12.10 Sales past 5Y21.50% Gross Margin18.00% 52W Low15.52% ATR0.12
Employees299 Current Ratio13.00 Sales Q/Q78.10% Oper. Margin- RSI (14)40.57 Volatility7.75% 7.60%
OptionableYes Debt/Eq0.01 EPS Q/Q-179.20% Profit Margin- Rel Volume0.90 Prev Close1.38
ShortableYes LT Debt/Eq0.01 EarningsMay 05 AMC Payout- Avg Volume6.46M Price1.34
Recom1.30 SMA20-11.67% SMA50-15.30% SMA200-55.02% Volume5,837,423 Change-2.90%
Jun-16-21Initiated BTIG Research Buy $10
Sep-24-20Initiated Ladenburg Thalmann Buy $1.25
Apr-08-20Initiated Oppenheimer Outperform $1.50
Jun-29-22 08:00AM  
Jun-16-22 08:00AM  
Jun-10-22 08:00AM  
Jun-09-22 09:00AM  
Jun-08-22 08:00AM  
Jun-03-22 08:00AM  
Jun-02-22 08:00AM  
May-26-22 07:39PM  
May-17-22 04:05PM  
May-13-22 08:00AM  
May-12-22 08:00AM  
May-07-22 10:01AM  
May-06-22 01:30AM  
May-05-22 06:05PM  
Apr-29-22 08:00AM  
Apr-28-22 04:30PM  
Apr-27-22 05:06AM  
Apr-14-22 08:00AM  
Apr-11-22 11:51AM  
Apr-08-22 02:19PM  
Apr-07-22 08:00AM  
Apr-06-22 08:00AM  
Apr-05-22 08:00AM  
Apr-01-22 08:35AM  
Mar-26-22 06:55AM  
Mar-25-22 08:00AM  
Mar-23-22 04:14PM  
Mar-22-22 07:00AM  
Mar-19-22 10:23AM  
Mar-18-22 06:49PM  
Mar-08-22 05:00PM  
Mar-07-22 08:00AM  
Mar-03-22 04:38PM  
Mar-01-22 08:30PM  
Feb-28-22 08:00AM  
Feb-24-22 04:29PM  
Feb-22-22 04:30PM  
Feb-17-22 06:00AM  
Feb-15-22 02:43PM  
Feb-14-22 08:00AM  
Feb-11-22 08:00AM  
Feb-09-22 04:30PM  
Feb-07-22 02:12PM  
Feb-04-22 02:04PM  
Feb-03-22 01:38PM  
Feb-02-22 08:00AM  
Jan-29-22 05:51AM  
Jan-26-22 08:00AM  
Jan-25-22 03:45PM  
Jan-20-22 08:00AM  
Jan-19-22 10:51PM  
Jan-13-22 09:40PM  
Jan-12-22 04:30PM  
Jan-11-22 05:11PM  
Jan-10-22 07:48PM  
Jan-07-22 08:00AM  
Jan-03-22 03:33PM  
Dec-29-21 08:00AM  
Dec-28-21 03:42PM  
Dec-27-21 06:00AM  
Dec-23-21 08:00AM  
Dec-22-21 08:05PM  
Dec-16-21 08:00AM  
Dec-14-21 10:35AM  
Dec-10-21 10:34AM  
Dec-09-21 08:00AM  
Dec-08-21 08:00AM  
Dec-03-21 03:18PM  
Dec-01-21 06:00AM  
Nov-29-21 10:00AM  
Nov-23-21 05:21PM  
Nov-22-21 08:00AM  
Nov-19-21 02:54PM  
Nov-15-21 08:00AM  
Nov-06-21 01:31AM  
Nov-05-21 05:47AM  
Nov-04-21 08:56PM  
Nov-03-21 08:00AM  
Nov-02-21 04:30PM  
Nov-01-21 10:00AM  
Oct-28-21 04:30PM  
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BARKER DAVID LDirectorMay 16Buy1.6010,00016,00013,894May 18 04:16 PM
Stewart Christopher P.Chief Financial OfficerMay 13Option Exercise0.5660,00033,600121,579May 16 09:31 PM
Holmlin R. ErikPresident and CEONov 29Buy3.995,02520,0375,025Dec 01 06:00 AM
Stewart Christopher P.Chief Financial OfficerNov 19Option Exercise0.5622,50012,60055,500Nov 23 06:00 AM